A Study of CT-388 in Participants Who Are Overweight or Obese with Type 2 Diabetes Mellitus

Eligibility Criteria

• * Male or female, 18 to 75 years of age
• * Body mass index (BMI) ≥25.0 kg/m\^2
• * Have a diagnosis of Type 2 Diabetes Mellitus (T2DM) according to the World Health Organization classification or other locally applicable standards
• * Have an HbA1c ≥7% and ≤10.5%
• * Management of T2DM with diet and exercise alone or diet and exercise and treatment with metformin or a sodium-glucose cotransporter-2 (SGLT-2) inhibitor as monotherapy or in combination, per approved local label
• * At least one self-reported unsuccessful diet/exercise effort to lose body weight
• * Have Type 1 Diabetes Mellitus (T1DM), history of ketosis or hyperosmolar state/coma, or any other types of diabetes except T2DM
• * Have had 1 or more episodes of Level 3 hypoglycemia or have had hypoglycemia unawareness within 3 months prior to screening
• * Have history or presence of proliferative diabetic retinopathy, diabetic macular edema, non-proliferative diabetic retinopathy that requires acute treatment
• * Have presence of active neuropathy (including resting tachycardia, orthostatic hypotension, or diabetic diarrhea)
• * Had treatment with any oral antihyperglycemic medications, with the exception of metformin or SGLT-2 inhibitors, within 3 months prior to screening or planned concurrent treatment with these medications during the study
• * Had treatment with injectable antihyperglycemic medication, with the exception of short-term insulin, within 6 months prior to screening or planned concurrent treatment with these medications during the study
• * Self-reported body weight change of \>5 kg within 3 months before screening
• * Any unbalanced/extreme diets, such as very low calorie, low carbohydrate, very high protein, ketogenic, or intermittent diets, within 3 months of the screening visit, or plan to be on such diets during the study
• * Current or recent participation in an organized weight reduction program
• * Current or recent use of any treatment that promotes weight loss or glucose metabolism
• * Current or recent use of treatment that may cause weight gain
• * Prior or planned surgical treatment for obesity
• * Clinically significant or active gastric emptying abnormality, malabsorption, or chronic use of medications that directly affect GI motility
• * History of chronic pancreatitis or acute pancreatitis within 6 months before screening
• * Have obesity induced by other endocrinologic disorders (e.g., Cushing syndrome) or diagnosed monogenetic or syndromic forms of obesity
• * History of major depressive disorder within 2 years of screening
• * Family or personal history of medullary thyroid carcinoma
• * Women who are pregnant, breastfeeding, or intend to become pregnant, or are of childbearing potential and not using a highly effective contraceptive method